Toronto Stock Exchange Symbol: LRI
LAVAL, QC, Feb. 9 /PRNewswire-FirstCall/ - LAB Research Inc. ("LRI", "LAB Research" or the "Company") (TSX: LRI), a Canadian-based global non-clinical contract research organization, today announced the nomination of Mr. Carl A. Spalding as Chairman of its Board of Directors in replacement of Mr. Karsten Skydsgaard who previously communicated a wish to step down of the Board to focus on his other professional obligations.
"On behalf of the Board of Directors, I would like to thank Karsten for his dedication and contribution to LAB Research since our 2006 Initial Public Offering ("IPO"). His expertise, and continuous support toward the Company have played a key role in LRI's development and success," said Mr. Luc Mainville, Chief Executive Officer and President of LAB Research.
Mr. Spalding brings to LRI extensive operational experience and contacts in the global pharmaceutical and contract research organization industries. Mr. Spalding has held numerous senior executive positions such as President and Chief Operating Officer of PAREXEL International Corporation, Executive Vice President and Group President, Healthcare Products Services at Cardinal Health and Vice President and General Manager, Ross Products for Abbott Laboratories.
"I am impressed with the timely execution and completion of the growth and development strategy put forward by the Senior Management team at LRI since its 2006 IPO. I am also confident that the recently adopted measures to insure a swift improvement of the Company's financial performance will prove to be successful and look forward to actively participating in the continued success of LAB Research," commented Mr. Spalding.
"We are very fortunate to have someone of Carl's calibre and with such industry experience and relationships to assume the Chairmanship of LAB Rese
|SOURCE LAB RESEARCH INC.|
Copyright©2009 PR Newswire.
All rights reserved